Itshac Ben-Dor, MD
Interventional Cardiology · Washington, DCNPI 1932356961
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,174 of the $25,472 with a category attached, or 63.5%. It is spread thinly across 38 manufacturers, the largest accounting for just 17.2%. Reporting peaked in 2024 at $9,724 and has fallen 70.8% since, to $2,840 in 2025.
Across 380 payments — averaging $67.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Medtronic$4K
- Abbott$4K
- Cordis US CORP.$2K
- Cathworks, Inc.$2K
- Ancora Heart, Inc.$1K
- plus $8K from 32 others
Across 679 payments — averaging $541.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- M.a. Med Alliance S.A.$152K
- Biotronik Inc.$150K
- Medalliance LLC$29K
- Essential Medical, Inc.$27K
- Bayer$9K
What the payments were for
- Consulting fees$4,90019%
- Travel & lodging$4,30017%
- Food & beverage$16,17463%
- Education$990%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 50 | $4,376 |
| Medtronic(2 entities) | 70 | $4,027 |
| Abbott | 43 | $3,827 |
| Cordis US CORP. | 1 | $2,400 |
| Cathworks, Inc. | 1 | $1,500 |
| Ancora Heart, Inc. | 6 | $1,469 |
| Teleflex LLC | 10 | $981 |
| Amgen | 29 | $844 |
| AstraZeneca | 37 | $782 |
| Arrow International, Inc. | 1 | $650 |
| Terumo Medical Corporation | 5 | $440 |
| Abiomed | 9 | $409 |
| Edwards Lifesciences | 7 | $360 |
| E.r. Squibb & Sons, L.L.C. | 12 | $322 |
| Cardiovascular Systems Inc. | 6 | $314 |
| Pfizer | 17 | $311 |
| Johnson & Johnson | 18 | $299 |
| Novo Nordisk | 10 | $242 |
| Jenavalve Technology, Inc. | 1 | $238 |
| Asahi Intecc USA, Inc. | 7 | $219 |
| Cook Medical LLC | 3 | $206 |
| Chiesi USA, Inc. | 4 | $173 |
| Shockwave Medical, Inc | 4 | $152 |
| Penumbra, Inc. | 1 | $150 |
| Biotronik Inc. | 2 | $148 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $125 |
| Novartis | 5 | $119 |
| Siemens Medical Solutions USA, Inc. | 1 | $88 |
| Cardiva Medical, Inc. | 2 | $53 |
| Celonova Biosciences, Inc. | 1 | $49 |
| Recor Medical Inc | 2 | $43 |
| Cardinal Health 200 LLC | 1 | $37 |
| Kestra Medical Technology Services, Inc. | 1 | $27 |
| Bard Peripheral Vascular, Inc. | 1 | $26 |
| Atricure, Inc. | 1 | $20 |
| Silk Road Medical, Inc. | 1 | $18 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Toray International America Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SELUTION SLRPCTA$2,400
- FFRangio$1,500
- AccuCinch$1,469
- COREVALVE EVOLUT R$1,442
- MANTA$450
- GENERAL - STRUCTURAL HEART$402
- CoreValve Evolut$358
- GlideWire$350
- DRAGONFLY OPSTAR$336
- SYMPLICITY G3$334
- AVVIGO Guidance System$292
- SYNERGY$290
- WATCHMAN Access System$287
- COROFLOW$285
- Impella$267
- OPTIS$254
- JenaValve Pericardial TAVR System$238
- Diamondback Coronary$237
- 3F$215
- PERCLOSE PROGLIDE$206
How this compares
Too few interventional cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 90 | $1,085 |
| Metoprolol Succinate | 40 | $694 |
| Furosemide | 37 | $140 |
| Atorvastatin Calcium | 14 | $106 |
| Prednisone | 13 | $25 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Washington
- Ron WaksmanWashington$915K
- Toby RogersWashington$880K
- Augusto PichardWashington$180K
- Lowell SatlerWashington$112K
- Jonathan ReinerWashington$77K
- Brian CaseWashington$63K
- Horst SievertWashington$58K
- Nelson BernardoWashington$55K
- Ramesh MazhariWashington$41K
- Nardos TemesgenWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.